Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research

Journal of Clinical Apheresis

Volumn 29, Issue 3, 2014, Pages 148-167

  Sarode, Ravi ^a   Bandarenko, Nick ^b   Brecher, Mark E ^c,d   Kiss, Joseph E ^e   Marques, Marisa B ^f   Szczepiorkowski, Zbigniew M ^g   Winters, Jeffrey L ^h  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LABORATORY CORPORATION OF AMERICA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f University of Alabama at Birmingham   (United States)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^h MAYO CLINIC   (United States)

Author keywords

ADAMTS13; microangiopathic hemolytic anemia; therapeutic plasma exchange; thrombotic thrombocytopenic purpura; Upshaw Shulman Syndrome

Indexed keywords

ALLOANTIBODY; ANTICOAGULANT AGENT; AUTOANTIBODY; COMPLEMENT FACTOR; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ADVERSE OUTCOME; ANALYTICAL PARAMETERS; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; CLINICAL DECISION MAKING; COMPLEMENT ACTIVATION; CONGENITAL DISORDER; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEVER; FLUORESCENCE RESONANCE ENERGY TRANSFER; FUTUROLOGY; GENERAL CONDITION DETERIORATION; GENETIC DISORDER; HEALTH CARE QUALITY; HUMAN; HYPERVOLEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LIMIT OF DETECTION; MEDICAL SOCIETY; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PLASMA TRANSFUSION; PREDICTIVE VALUE; PROTEIN DEFICIENCY; RELAPSE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; APHERESIS; BLOOD; CLASSIFICATION; CONSENSUS DEVELOPMENT; DEFICIENCY; HEALTH CARE ORGANIZATION; PLASMAPHERESIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; UNITED STATES;

ADAM PROTEINS; BLOOD COMPONENT REMOVAL; HUMANS; PLASMA EXCHANGE; PLATELET TRANSFUSION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SOCIETIES, SCIENTIFIC; UNITED STATES;

EID: 84902529329     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21302     Document Type: Review

References (69)

1. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Ginsburg D, Tsai HM,. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494. (Pubitemid 32938741)
2. Tsai HM, Lian EC,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594. (Pubitemid 28536133)
3. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B,. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584. (Pubitemid 28536132)
4. George JN,. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060-4069.
5. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasroff RA,. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397.
6. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D,. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435. (Pubitemid 13234018)
7. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN., Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511; quiz 1662.
8. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE,. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049. (Pubitemid 38685342)
9. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP,. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011; 8: e1001013.
10. Kremer Hovinga JA, Lämmle B,. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program 2012; 2012: 610-616.
11. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE,. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950. (Pubitemid 26357374)
12. Tsai HM, Li A, Rock G,. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001; 47: 387-392. (Pubitemid 32685483)
13. Tsai H-M., Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl 2009: S11-S14.
14. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y,. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 11902-11907. (Pubitemid 34994496)
15. Jang MJ, Kim NK, Chong SY, Kim HJ, Lee SJ, Kang MS, Oh D,. Frequency of Pro475Ser polymorphism of ADAMTS13 gene and its association with ADAMTS-13 activity in the Korean population. Yonsei Med J 2008; 49: 405-408.
16. Akiyama M, Kokame K, Miyata T,. ADAMTS13 P475S polymorphism causes a lowered enzymatic activity and urea lability in vitro. J Thromb Haemost 2008; 6: 1830-1832.
17. Tsai H-M,. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost 2012; 38: 469-482.
18. Studt J-D, Böhm M, Budde U, Girma J-P, Varadi K, Lämmle B,. Measurement of von Willebrand factor-cleaving protease (ADAMTS -13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 1: 1882-1887.
19. Tripodi A, Chantarangkul V, Böhm M, Budde U, Dong J-F, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Syudt JD, Turecek PL, Mannucci PM,. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-1609. (Pubitemid 40186177)
20. Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT, Chung DW, Ferrari S, Fujimura Y, Karimi M, Kokame K, Kremer Hovinga JA, Lammle B, de Meyer SF, Plaimauer B, Vanhoorelbeke K, Varadi K, Mannucci PM,. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008; 6: 1534-1541.
21. Fontana S, Kremer Hovinga JA, Studt J-D, Alberio L, Lämmle B, Taleghani BM,. Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol 2004; 41: 48-59. (Pubitemid 38057785)
22. Meyer SC, Sulzer I, Lämmle B, Kremer Hovinga JA,. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 5: 866-867. (Pubitemid 46563591)
23. Eckmann CM, De Laaf RTM, Van Keulen JM, Van Mourik JA, De Laat B,. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETS-VWF73 assay. J Thromb Haemost 2007; 5: 1330-1331. (Pubitemid 46902141)
24. Kremer Hovinga JA, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, ten Cate H, Reitsma PH, Wuillemin WA, Lammle B,. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost JTH 2007; 5: 2284-2290. (Pubitemid 47617882)
25. Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, Deckmyn H, Legendre P, Diehl JL, Brauch D,. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35: 2375-2382. (Pubitemid 47476237)
26. Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Lösche W, Reinhart K, Brunkhorst FM,. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008; 93: 137-140. (Pubitemid 351156164)
27. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y,. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534. (Pubitemid 43076375)
28. Hunt BJ, Lämmle B, Nevard CH, Haycock GB, Furlan M,. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2001; 85: 975-978. (Pubitemid 32573745)
29. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP,. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-1772.
30. Rick ME, Moll S, Taylor MA, Krizek DM, White GC 2nd, Aronson DL,. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2002; 88: 598-604. (Pubitemid 35174001)
31. Kremer Hovinga JA, Studt J-D, Alberio L, Lämmle B,. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 2004; 41: 75-82. (Pubitemid 38057788)
32. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Fremeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K,. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004; 83: 233-244. (Pubitemid 38955446)
33. Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM,. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004; 127: 433-439. (Pubitemid 39536596)
34. Tsai H-M,. ADAMTS13 and microvascular thrombosis. Expert Rev Cardiovasc Ther 2006; 4: 813-825. (Pubitemid 46017521)
35. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F,. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7: 1703-1710.
36. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-1267. (Pubitemid 41129589)
37. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Reti M, Mikovic M, Giuffrida G, Laurenti L, Mannucci PM,. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239. (Pubitemid 351397711)
38. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ,. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-1753.
39. Bell WR, Braine HG, Ness PM, Kickler TS,. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403.
40. Rock G, Shumak K, Kelton J, Blanchette VS, Buskard N, Nair R, Spasoff R,. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group. Transfusion (Paris) 1992; 32: 710-714.
41. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K,. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985; 38: 469-479. (Pubitemid 15041946)
42. Byrnes JJ, Moake JL,. Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy. Clin Haematol 1986; 15: 413-442. (Pubitemid 16028879)
43. Rock G, Anderson D, Clark W, Leblond P, Palmer D, Sternbach M, Sutton D, Wells G, Canadian Apheresis Group, Canadian Association of Apheresis Nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura?. No answer yet. Br J Haematol 2005; 129: 79-86. (Pubitemid 40524055)
44. Tandon NN, Rock G, Jamieson GA,. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994; 88: 816-825. (Pubitemid 24375798)
45. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P,. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40: 104-111.
46. Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lämmle B, et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion (Paris) 2012; 52: 2525-2532; quiz 2524.
47. Cataland SR, Jin M, Ferketich AK, Kennedy MS, Kraut EH, George JN, et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136: 146-149. (Pubitemid 44912601)
48. Kremer Hovinga JA, Studt J-D, Demarmels Biasiutti F, Solenthaler M, Alberio L, Zwicky C, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica 2004; 89: 320-324. (Pubitemid 38788417)
49. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN,. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion (Paris) 2009; 49: 873-887.
50. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F,. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31: 11-19.
51. Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9(Suppl1): 283-301.
52. Tao Z, Anthony K, Peng Y, Choi H, Nolasco L, Rice L, Moake JL, Dong JF,. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 1931-1935. (Pubitemid 44226771)
53. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D,. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-2761. (Pubitemid 41434402)
54. Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD,. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion (Paris) 2007; 47: 120-125. (Pubitemid 46006319)
55. Scully M, Gattens M, Khair K, Liesner R,. The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2006; 135: 101-104. (Pubitemid 44337670)
56. Waters AM, Licht C,. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol Berl Ger 2011; 26: 41-57.
57. Schiviz A, Wuersch K, Piskernik C, Dietrich B, Hoellriegl W, Rottensteiner H, Scheiflinger F, Schwarz HP, Muchitsch EM,. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 2012; 119: 6128-6135.
58. Raife T, Friedman KD, Fenwick B,. Lepirudin prevents lethal effects of Shiga toxin in a canine model. Thromb Haemost 2004; 92: 387-393. (Pubitemid 39172320)
59. Plaimauer B, Zimmermann K, Völkel D, Antoine G, Kerschbaumer R, Jenab P, Furlan M, Gerritsen H, Lammle B, Schwartz HP, Scheiflinger F,. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100: 3626-3632. (Pubitemid 35303932)
60. Plaimauer B, Kremer Hovinga JA, Juno C, Wolfsegger MJ, Skalicky S, Schmidt M, Grillberger L, Hasslacher M, Knobl P, Ehrlich H, Scheiflinger F,. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011; 9: 936-944.
61. Phillips MD, Moake JL, Nolasco L, Turner N,. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood 1988; 72: 1898-1903. (Pubitemid 19030875)
62. Weinstein M, Vosburgh E, Phillips M, Turner N, Chute-Rose L, Moake J. Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib,. Comparison with other polyanionic and polyaromatic polymers. Blood 1991; 78: 2291-2298.
63. Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hrinda ME, McIntire LV,. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993; 81: 1263-1276. (Pubitemid 23067364)
64. Diener JL, Daniel Lagassé HA, Duerschmied D, Merhi Y, Tanguay J-F, Hutabarat R, Gilbert J. Wagner DD. Schaub R,. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 2009; 7: 1155-1162.
65. Mayr FB, Knöbl P, Jilma B, Siller-Matula JM, Wagner PG, Schaub RG, Gilbert JC., Jilma-Stohlawetz P,. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion (Paris) 2010; 50: 1079-1087.
66. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knöbl P,. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 105: 545-552.
67. Cataland SR, Peyvandi F, Mannucci PM, Lämmle B, Kremer Hovinga JA, Machin SJ, Scully M., Rock G., Gilbert JC., Yang S., Wu H., Jilma B., Knoebl P,. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol 2012; 87: 430-432.
68. Holz J-B,. The TITAN trial - assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 2012; 46: 343-346.
69. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, Ni H, Lopez JA,. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121: 593-603.